Skip to main content
. Author manuscript; available in PMC: 2020 Apr 14.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2019 Oct 14;23(1):184–193. doi: 10.1038/s41391-019-0176-8

Fig. 1.

Fig. 1.

Outcomes in men with oligometastatic prostate cancer treated with whole prostate cryoablation in combination with androgen deprivation therapy and pembrolizumab. A, Waterfall plot of the best PSA response (percent fold change compared to baseline). B-D, Kaplan Meir survival analysis of (B) PSA progression-free, (C) systemic therapy-free, and (D) CRPC progression-free survival. E, Swimmers plots of PSA progression, new systemic therapy, CRPC, and death.